[1] JIANG YZ,NIE HM,WANG R. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. J Clin Hepatol,2019,35(11):2588-2591.(in Chinese)姜煜资,聂红明,汪蓉.非酒精性脂肪性肝病的发病机制[J].临床肝胆病杂志,2019,35(11):2588-2591.
|
[2] FRIEDMAN SL,NEUSCHWANDER BA,MARY R,et al. Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922.
|
[3] PIMPIN L,CORTEZ-PINTO H,NEGRO F,et al. Burden of liver disease in Europe:Epidemiology and analysis of risk factors to identify prevention policies[J]. J Hepatol,2018,69(3):718-738.
|
[4] ARAU'JO AR,ROSSO N,BEDOGNI G,et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis:What we need in the future[J]. Liver Int,2018,38(Suppl 1):47-51.
|
[5] CORTE CD,MAZZOTTA AR,NOBILI V. Fatty liver disease and obesity in youth[J]. Curr Opin Endocrinol Diabetes Obes,2016,23(1):66-71.
|
[6] GUREEV AP,SHMATKOVA ML,BASHMAKOV VY,et al. The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes[J]. Biomed Khim,2016,10(1):70-74.
|
[7] LEFEBVRE P. Sorting out the roles of PPARαin energy metabolism and vascular homeostasis[J]. J Clin Invest,2006,116(3):571-580.
|
[8] HUANG FF,WANG JJ,YU FM,et al. Protective effect of meretrix meretrix oligopeptides on high-fat-diet-induced nonalcoholic fatty liver disease in mice[J]. Mar Drugs,2018,16(2):39-55.
|
[9] ZHANG D,MA LQ. Research advances in the role and mechanism of peroxisome proliferator-activated receptor alpha in liver diseases[J]. J Clin Hepatol,2019,35(10):2351-2354.(in Chinese)张丹,马岚青.过氧化物酶体增殖激活受体α在肝脏疾病中的作用及机制[J].临床肝胆病杂志,2019,35(10):2351-2354.
|
[10] MONTAGNER A,POLIZZI A,FOUCHE E,et al. Original article:Liver PPARαis crucial for whole-body fatty acid homeostasis and is protective against NAFLD[J]. Gut,2016,65(7):1202-1214.
|
[11] YAO FF,JIA RP,HUANG H,et al. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease[J]. Arch Med Sci,2019,15(5):1336-1334.
|
[12] LU S,ZHANG T,GU W,et al. Volatile oil of amomum villosum inhibits nonalcoholic fatty liver disease via the gut-liver axis[J]. Bio Med Res Int,2018,7(19):35-48.
|
[13] LI F,SUN G,WANG ZK,et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients[J]. Sci China Life Sci,2018,61(7):770-778.
|
[14] QUAN M,XING HC. Research progress on intestinal flora and chronic liver diseases[J/CD]. Chin J Liver Dis(Electronic Version),2019,11(3):26-30.(in Chinese)全敏,邢卉春.肠道菌群与慢性肝病相关研究进展[J/CD].中国肝脏病杂志(电子版),2019,11(3):26-30.
|
[15] MA JL,ZHOU QH,LI HK. Gut microbiota and nonalcoholic fatty liver disease:Insights on mechanisms and therapy[J].Nutrients,2017,9(10):e1124.
|
[16] YU X,WANG WJ,JIN JY,et al. Linggui Zhugan decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2019,35(5):891-894.(in Chinese)喻晓,王雯婕,金嘉悦,等.苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J].长春中医药大学学报,2019,35(5):891-894.
|
[17] LIU HL,LIU MH,FU XQ,et al. Astaxanthin prevents alcoholic fatty liver disease by modulating mouse gut microbiota[J].Nutrients,2018,10(9):1298-1315.
|
[18] YOUNGMI J,INYOUNG K,MOHAMED M,et al. Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease[J]. Food Sci Biotechnol,2018,28(1):261-267.
|
[19] GUO J,CHEN YY,YE F. Therapeutic efects of fenofibrate on nonalcoholic faty liver disease in vitro and related mechanism[J]. Acta Med Univ Sci Technol Huazhong,2017,46(3):265-270.(in Chinese)郭骏,陈玉媛,叶枫.非诺贝特缓解非酒精性脂肪性肝病的体外机制研究[J].华中科技大学学报:医学版,2017,46(3):265-270.
|
[20] ZHANG N,LU Y,SHEN X,et al. Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice[J]. Pharmacology,2015,95(3-4):173-180.
|
[21] HOJYO S,FUKADA T. Zinc transporters and signaling in physiology and pathogenesis[J]. Arch Biochem Biophys,2016,611:43-50.
|
[22] NAN J,YANG SX. Research advances in non-statin drugs for lipid regulation[J]. Chin J Geriatr Heart Brain Vess Dis,2016,18(6):655-658.(in Chinese)南京,杨水祥.非他汀类调脂药物的研究进展[J].中华老年心脑血管病杂志,2016,18(6):655-658.
|
[23] SUK KT,KIM DJ. Gut microbiota:Novel therapeutic target for nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol,2019,13(3):193-204.
|
[24] LIU CC,LI W,WANG LY. Relationship between gut microbiota and non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol,2017,26(10):1103-1106.(in Chinese)刘晨晨,李稳,王凌云.肠道菌群与非酒精性脂肪性肝病关系的研究进展[J].胃肠病学和肝病学杂志,2017,26(10):1103-1106.
|
[25] LU M,TANG YC,LI M,et al. Co-administration of cholesterol-lowering probiotics and anthraquinone from cassia obtusifolia l. ameliorate non-alcoholic fatty liver[J]. PLo S One,2015,10(9):e0138078.
|
[26] LIU BH,ZHANG J,SUN P,et al. Raw bowl tea(tuocha)polyphenol prevention of nonalcoholic fatty liver disease by regulating intestinal function in mice[J]. Biomolecules,2019,9(435):1-20.
|